Usual Nicotine Content Cigarettes
PreclinicalSmall molecule
Usual Nicotine Content Cigarettes is one of 30 small molecule programs targeting Anxiety Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Anxiety Disorder
#DrugCompanyPhaseTrials
1Brintellix
TakedaApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Buspar
Bristol-Myers SquibbApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Mifeprex
DDanco
Approved
Methylphenidate Hydrochloride
TakedaApproved
Valium
Akero TherapeuticsApproved
Ativan
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMilton S. Hershey Medical Center